世界の乳がん治療薬市場2023-2027

【英語タイトル】Global Breast Cancer Therapeutics Market 2023-2027

Technavioが出版した調査資料(IRTNTR74565-23)・商品コード:IRTNTR74565-23
・発行会社(調査会社):Technavio
・発行日:2023年6月2日
・ページ数:約120
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:北米、ヨーロッパ、アジア、その他地域
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥380,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥608,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

乳がん治療薬の世界市場 2023-2027
乳がん治療薬市場は2022-2027年に130億2739万米ドルで成長し、予測期間中のCAGRは8.23%で加速すると予測されます。この調査レポートは、乳がん治療薬市場の全体的な分析、市場規模と予測、動向、成長促進要因、課題、さらに約25のベンダーを網羅したベンダー分析を掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。乳がんの有病率の上昇、堅調なパイプラインと新薬承認、患者支援イニシアチブの増加などが市場を牽引しています。

Technavio社の乳がん治療薬市場は以下のように分類されます:

疾患タイプ別
- 浸潤性乳がん
- 非浸潤性乳管がん

治療法別
- 標的療法
- ホルモン療法
- 化学療法

地域別
- 北米
- ヨーロッパ
- アジア
- その他の地域(ROW)

本調査では、今後数年間の乳がん治療薬市場の成長を促進する主な要因の1つとして、新たな新規治療法を挙げています。また、改善された診断モダリティの利用可能性と戦略的コラボレーションの増加は、市場の大規模な需要につながると考えられます。

当レポートでは、乳がん治療薬市場について以下の分野をカバーしています:
- 乳がん治療薬市場の規模
- 乳がん治療薬市場の予測
- 乳がん治療薬市場の産業分析

強固なベンダー分析は、クライアントが市場での地位を向上できるように設計されており、これに沿って本レポートでは、AbbVie Inc.、Amgen Inc.、AstraZeneca、Bristol Myers Squibb、Clovis Oncology、Daiichi Sankyo Co. Ltd.、Eisai Co. Ltd.、Eli Lilly and Co.、Exelixis Inc.、F. Hoffmann La Roche Ltd.、GlaxoSmithKline Plc、Merck and Co. Inc.、NanoString Technologies Inc.、Novartis AG、Perkin Elmer Inc.、Pfizer Inc.、Puma Biotechnology Inc.、Sanofi、Teva Pharmaceutical Industries Ltd.、Viatris Inc. などの企業情報が含まれています。また、乳がん治療薬市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。本レポートには、主要ベンダーの分析に加え、包括的な市場およびベンダーランドスケープが含まれています。

当出版社は、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、総括する方法で、市場の詳細なイメージを提示しています。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示しています。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。市場調査報告書は、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

1.エグゼクティブサマリー
2.市場状況
3.市場規模
4.過去の市場規模
5.ファイブフォース分析
6.乳がん治療薬の世界市場:疾患タイプ別
7.乳がん治療薬の世界市場:治療法別
8.顧客状況
9.地域別
10.推進要因・課題・動向
11.企業状況
12.企業分析
13.付録

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Disease Type
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Therapy
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global breast cancer therapeutics market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on global breast cancer therapeutics market 2017 – 2021 ($ million)
o 4.2 Disease type Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Disease type Segment 2017 – 2021 ($ million)
o 4.3 Therapy Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Therapy Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Disease Type
o 6.1 Market segments
o Exhibit 30: Chart on Disease Type – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Disease Type – Market share 2022-2027 (%)
o 6.2 Comparison by Disease Type
o Exhibit 32: Chart on Comparison by Disease Type
o Exhibit 33: Data Table on Comparison by Disease Type
o 6.3 Invasive breast cancers – Market size and forecast 2022-2027
o Exhibit 34: Chart on Invasive breast cancers – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Invasive breast cancers – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Invasive breast cancers – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Invasive breast cancers – Year-over-year growth 2022-2027 (%)
o 6.4 Ductal carcinoma in situ – Market size and forecast 2022-2027
o Exhibit 38: Chart on Ductal carcinoma in situ – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Ductal carcinoma in situ – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Ductal carcinoma in situ – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Ductal carcinoma in situ – Year-over-year growth 2022-2027 (%)
o 6.5 Market opportunity by Disease Type
o Exhibit 42: Market opportunity by Disease Type ($ million)
o Exhibit 43: Data Table on Market opportunity by Disease Type ($ million)
• 7 Market Segmentation by Therapy
o 7.1 Market segments
o Exhibit 44: Chart on Therapy – Market share 2022-2027 (%)
o Exhibit 45: Data Table on Therapy – Market share 2022-2027 (%)
o 7.2 Comparison by Therapy
o Exhibit 46: Chart on Comparison by Therapy
o Exhibit 47: Data Table on Comparison by Therapy
o 7.3 Targeted therapy – Market size and forecast 2022-2027
o Exhibit 48: Chart on Targeted therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 49: Data Table on Targeted therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 50: Chart on Targeted therapy – Year-over-year growth 2022-2027 (%)
o Exhibit 51: Data Table on Targeted therapy – Year-over-year growth 2022-2027 (%)
o 7.4 Hormonal therapy – Market size and forecast 2022-2027
o Exhibit 52: Chart on Hormonal therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Data Table on Hormonal therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 54: Chart on Hormonal therapy – Year-over-year growth 2022-2027 (%)
o Exhibit 55: Data Table on Hormonal therapy – Year-over-year growth 2022-2027 (%)
o 7.5 Chemotherapy – Market size and forecast 2022-2027
o Exhibit 56: Chart on Chemotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Data Table on Chemotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 58: Chart on Chemotherapy – Year-over-year growth 2022-2027 (%)
o Exhibit 59: Data Table on Chemotherapy – Year-over-year growth 2022-2027 (%)
o 7.6 Market opportunity by Therapy
o Exhibit 60: Market opportunity by Therapy ($ million)
o Exhibit 61: Data Table on Market opportunity by Therapy ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 63: Chart on Market share By Geographical Landscape 2022-2027 (%)
o Exhibit 64: Data Table on Market share By Geographical Landscape 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 65: Chart on Geographic comparison
o Exhibit 66: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 67: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 68: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 69: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 70: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 71: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 72: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 73: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 74: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 75: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 76: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 77: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 78: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 79: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 80: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 81: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 82: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 83: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 84: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 85: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 86: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 Germany – Market size and forecast 2022-2027
o Exhibit 87: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 88: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 89: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 90: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.9 Canada – Market size and forecast 2022-2027
o Exhibit 91: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 92: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 93: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 94: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.10 UK – Market size and forecast 2022-2027
o Exhibit 95: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 96: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 97: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 98: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.11 China – Market size and forecast 2022-2027
o Exhibit 99: Chart on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 100: Data Table on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 101: Chart on China – Year-over-year growth 2022-2027 (%)
o Exhibit 102: Data Table on China – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 103: Market opportunity By Geographical Landscape ($ million)
o Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 105: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 107: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 108: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 109: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 110: Matrix on vendor position and classification
o 12.3 AbbVie Inc.
o Exhibit 111: AbbVie Inc. – Overview
o Exhibit 112: AbbVie Inc. – Product / Service
o Exhibit 113: AbbVie Inc. – Key news
o Exhibit 114: AbbVie Inc. – Key offerings
o 12.4 Amgen Inc.
o Exhibit 115: Amgen Inc. – Overview
o Exhibit 116: Amgen Inc. – Product / Service
o Exhibit 117: Amgen Inc. – Key offerings
o 12.5 AstraZeneca
o Exhibit 118: AstraZeneca – Overview
o Exhibit 119: AstraZeneca – Product / Service
o Exhibit 120: AstraZeneca – Key news
o Exhibit 121: AstraZeneca – Key offerings
o 12.6 Bristol Myers Squibb
o Exhibit 122: Bristol Myers Squibb – Overview
o Exhibit 123: Bristol Myers Squibb – Product / Service
o Exhibit 124: Bristol Myers Squibb – Key news
o Exhibit 125: Bristol Myers Squibb – Key offerings
o 12.7 Clovis Oncology
o Exhibit 126: Clovis Oncology – Overview
o Exhibit 127: Clovis Oncology – Business segments
o Exhibit 128: Clovis Oncology – Key offerings
o Exhibit 129: Clovis Oncology – Segment focus
o 12.8 Daiichi Sankyo Co. Ltd.
o Exhibit 130: Daiichi Sankyo Co. Ltd. – Overview
o Exhibit 131: Daiichi Sankyo Co. Ltd. – Product / Service
o Exhibit 132: Daiichi Sankyo Co. Ltd. – Key news
o Exhibit 133: Daiichi Sankyo Co. Ltd. – Key offerings
o 12.9 Eli Lilly and Co.
o Exhibit 134: Eli Lilly and Co. – Overview
o Exhibit 135: Eli Lilly and Co. – Product / Service
o Exhibit 136: Eli Lilly and Co. – Key news
o Exhibit 137: Eli Lilly and Co. – Key offerings
o 12.10 Exelixis Inc.
o Exhibit 138: Exelixis Inc. – Overview
o Exhibit 139: Exelixis Inc. – Product / Service
o Exhibit 140: Exelixis Inc. – Key offerings
o 12.11 F. Hoffmann La Roche Ltd.
o Exhibit 141: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 142: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 143: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 144: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 145: F. Hoffmann La Roche Ltd. – Segment focus
o 12.12 GlaxoSmithKline Plc
o Exhibit 146: GlaxoSmithKline Plc – Overview
o Exhibit 147: GlaxoSmithKline Plc – Business segments
o Exhibit 148: GlaxoSmithKline Plc – Key news
o Exhibit 149: GlaxoSmithKline Plc – Key offerings
o Exhibit 150: GlaxoSmithKline Plc – Segment focus
o 12.13 Merck and Co. Inc.
o Exhibit 151: Merck and Co. Inc. – Overview
o Exhibit 152: Merck and Co. Inc. – Business segments
o Exhibit 153: Merck and Co. Inc. – Key news
o Exhibit 154: Merck and Co. Inc. – Key offerings
o Exhibit 155: Merck and Co. Inc. – Segment focus
o 12.14 NanoString Technologies Inc.
o Exhibit 156: NanoString Technologies Inc. – Overview
o Exhibit 157: NanoString Technologies Inc. – Product / Service
o Exhibit 158: NanoString Technologies Inc. – Key offerings
o 12.15 Novartis AG
o Exhibit 159: Novartis AG – Overview
o Exhibit 160: Novartis AG – Business segments
o Exhibit 161: Novartis AG – Key offerings
o Exhibit 162: Novartis AG – Segment focus
o 12.16 Perkin Elmer Inc.
o Exhibit 163: Perkin Elmer Inc. – Overview
o Exhibit 164: Perkin Elmer Inc. – Business segments
o Exhibit 165: Perkin Elmer Inc. – Key news
o Exhibit 166: Perkin Elmer Inc. – Key offerings
o Exhibit 167: Perkin Elmer Inc. – Segment focus
o 12.17 Pfizer Inc.
o Exhibit 168: Pfizer Inc. – Overview
o Exhibit 169: Pfizer Inc. – Product / Service
o Exhibit 170: Pfizer Inc. – Key news
o Exhibit 171: Pfizer Inc. – Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 172: Inclusions checklist
o Exhibit 173: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 174: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 175: Research methodology
o Exhibit 176: Validation techniques employed for market sizing
o Exhibit 177: Information sources
o 13.5 List of abbreviations
o Exhibit 178: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market By Geographical Landscape
Exhibits5: Executive Summary – Chart on Market Segmentation by Disease Type
Exhibits6: Executive Summary – Chart on Market Segmentation by Therapy
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on global breast cancer therapeutics market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Disease type Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Therapy Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Disease Type – Market share 2022-2027 (%)
Exhibits31: Data Table on Disease Type – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Disease Type
Exhibits33: Data Table on Comparison by Disease Type
Exhibits34: Chart on Invasive breast cancers – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Invasive breast cancers – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Invasive breast cancers – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Invasive breast cancers – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Ductal carcinoma in situ – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Ductal carcinoma in situ – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Ductal carcinoma in situ – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Ductal carcinoma in situ – Year-over-year growth 2022-2027 (%)
Exhibits42: Market opportunity by Disease Type ($ million)
Exhibits43: Data Table on Market opportunity by Disease Type ($ million)
Exhibits44: Chart on Therapy – Market share 2022-2027 (%)
Exhibits45: Data Table on Therapy – Market share 2022-2027 (%)
Exhibits46: Chart on Comparison by Therapy
Exhibits47: Data Table on Comparison by Therapy
Exhibits48: Chart on Targeted therapy – Market size and forecast 2022-2027 ($ million)
Exhibits49: Data Table on Targeted therapy – Market size and forecast 2022-2027 ($ million)
Exhibits50: Chart on Targeted therapy – Year-over-year growth 2022-2027 (%)
Exhibits51: Data Table on Targeted therapy – Year-over-year growth 2022-2027 (%)
Exhibits52: Chart on Hormonal therapy – Market size and forecast 2022-2027 ($ million)
Exhibits53: Data Table on Hormonal therapy – Market size and forecast 2022-2027 ($ million)
Exhibits54: Chart on Hormonal therapy – Year-over-year growth 2022-2027 (%)
Exhibits55: Data Table on Hormonal therapy – Year-over-year growth 2022-2027 (%)
Exhibits56: Chart on Chemotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits57: Data Table on Chemotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits58: Chart on Chemotherapy – Year-over-year growth 2022-2027 (%)
Exhibits59: Data Table on Chemotherapy – Year-over-year growth 2022-2027 (%)
Exhibits60: Market opportunity by Therapy ($ million)
Exhibits61: Data Table on Market opportunity by Therapy ($ million)
Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits63: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits64: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits65: Chart on Geographic comparison
Exhibits66: Data Table on Geographic comparison
Exhibits67: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits68: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits69: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits70: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits71: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits72: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits73: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits74: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits75: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits76: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits77: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits78: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits79: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits80: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits81: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits82: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits83: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits99: Chart on China – Market size and forecast 2022-2027 ($ million)
Exhibits100: Data Table on China – Market size and forecast 2022-2027 ($ million)
Exhibits101: Chart on China – Year-over-year growth 2022-2027 (%)
Exhibits102: Data Table on China – Year-over-year growth 2022-2027 (%)
Exhibits103: Market opportunity By Geographical Landscape ($ million)
Exhibits104: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits105: Impact of drivers and challenges in 2022 and 2027
Exhibits106: Overview on Criticality of inputs and Factors of differentiation
Exhibits107: Overview on factors of disruption
Exhibits108: Impact of key risks on business
Exhibits109: Vendors covered
Exhibits110: Matrix on vendor position and classification
Exhibits111: AbbVie Inc. – Overview
Exhibits112: AbbVie Inc. – Product / Service
Exhibits113: AbbVie Inc. – Key news
Exhibits114: AbbVie Inc. – Key offerings
Exhibits115: Amgen Inc. – Overview
Exhibits116: Amgen Inc. – Product / Service
Exhibits117: Amgen Inc. – Key offerings
Exhibits118: AstraZeneca – Overview
Exhibits119: AstraZeneca – Product / Service
Exhibits120: AstraZeneca – Key news
Exhibits121: AstraZeneca – Key offerings
Exhibits122: Bristol Myers Squibb – Overview
Exhibits123: Bristol Myers Squibb – Product / Service
Exhibits124: Bristol Myers Squibb – Key news
Exhibits125: Bristol Myers Squibb – Key offerings
Exhibits126: Clovis Oncology – Overview
Exhibits127: Clovis Oncology – Business segments
Exhibits128: Clovis Oncology – Key offerings
Exhibits129: Clovis Oncology – Segment focus
Exhibits130: Daiichi Sankyo Co. Ltd. – Overview
Exhibits131: Daiichi Sankyo Co. Ltd. – Product / Service
Exhibits132: Daiichi Sankyo Co. Ltd. – Key news
Exhibits133: Daiichi Sankyo Co. Ltd. – Key offerings
Exhibits134: Eli Lilly and Co. – Overview
Exhibits135: Eli Lilly and Co. – Product / Service
Exhibits136: Eli Lilly and Co. – Key news
Exhibits137: Eli Lilly and Co. – Key offerings
Exhibits138: Exelixis Inc. – Overview
Exhibits139: Exelixis Inc. – Product / Service
Exhibits140: Exelixis Inc. – Key offerings
Exhibits141: F. Hoffmann La Roche Ltd. – Overview
Exhibits142: F. Hoffmann La Roche Ltd. – Business segments
Exhibits143: F. Hoffmann La Roche Ltd. – Key news
Exhibits144: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits145: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits146: GlaxoSmithKline Plc – Overview
Exhibits147: GlaxoSmithKline Plc – Business segments
Exhibits148: GlaxoSmithKline Plc – Key news
Exhibits149: GlaxoSmithKline Plc – Key offerings
Exhibits150: GlaxoSmithKline Plc – Segment focus
Exhibits151: Merck and Co. Inc. – Overview
Exhibits152: Merck and Co. Inc. – Business segments
Exhibits153: Merck and Co. Inc. – Key news
Exhibits154: Merck and Co. Inc. – Key offerings
Exhibits155: Merck and Co. Inc. – Segment focus
Exhibits156: NanoString Technologies Inc. – Overview
Exhibits157: NanoString Technologies Inc. – Product / Service
Exhibits158: NanoString Technologies Inc. – Key offerings
Exhibits159: Novartis AG – Overview
Exhibits160: Novartis AG – Business segments
Exhibits161: Novartis AG – Key offerings
Exhibits162: Novartis AG – Segment focus
Exhibits163: Perkin Elmer Inc. – Overview
Exhibits164: Perkin Elmer Inc. – Business segments
Exhibits165: Perkin Elmer Inc. – Key news
Exhibits166: Perkin Elmer Inc. – Key offerings
Exhibits167: Perkin Elmer Inc. – Segment focus
Exhibits168: Pfizer Inc. – Overview
Exhibits169: Pfizer Inc. – Product / Service
Exhibits170: Pfizer Inc. – Key news
Exhibits171: Pfizer Inc. – Key offerings
Exhibits172: Inclusions checklist
Exhibits173: Exclusions checklist
Exhibits174: Currency conversion rates for US$
Exhibits175: Research methodology
Exhibits176: Validation techniques employed for market sizing
Exhibits177: Information sources
Exhibits178: List of abbreviations



★調査レポート[世界の乳がん治療薬市場2023-2027] (コード:IRTNTR74565-23)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の乳がん治療薬市場2023-2027]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆